Gritstone Oncology

Gritstone Oncology is developing targeted immunotherapies for cancer and infectious disease. Gritstone's approach seeks to generate a therapeutic immune response by leveraging insights into the immune system's ability to recognize and destroy diseased cells by targeting select antigens. Gritstone is also developing a second-generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both prolonged protection and potency, including against emerging Spike mutant forms of SARS-CoV-2, as well as a collaboration with Gilead Sciences to research and develop a vaccine-based immunotherapy as part of Gilead's efforts to cure patients with human immunodeficiency virus (HIV) infection

Gritstone leverages a Nextflow-driven, cloud-based, shared job queue to dispatch data pipeline and machine learning workloads. Seqera Platform is also utilized and provides a powerful console for monitoring, managing, and sharing pipelines. The compute resources are dynamically provisioned via AWS Batch based on the process requirements for CPU, GPU, and memory, providing efficient cloud utilization and reduced spending through the combination of on-demand and spot instances.

"Gritstone has partnered with Seqera for Nextflow and Seqera Platform to manage our genomics data & machine learning workflow needs. We are excited about the direction the Seqera team is taking their solutions and are looking forward to playing our part in advancing this technology for the industry as a whole."